Biosante Pharmaceuticals Aktie

Biosante Pharmaceuticals für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1W15D / ISIN: US00182C1036

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
14.03.2025 12:51:51

ANI Pharma Says FDA Approves Expanded ILUVIEN Label To Treat Chronic NIU-PS

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) announced Friday that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

The approval also includes other updates to the label including to the Warnings and Precautions section.

The Company plans to market ILUVIEN for chronic NIU-PS in addition to its current indication of diabetic macular edema (DME) in the U.S. ILUVIEN is already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries.

ANI previously announced that it extended its supply agreement for ILUVIEN with a subsidiary of Siegfried Holding AG through 2029. Siegfried and ANI also agreed to upgrade equipment on the existing manufacturing line and significantly expand capacity.

Analysen zu Biosante Pharmaceuticals Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Biosante Pharmaceuticals Inc 75,50 0,00% Biosante Pharmaceuticals Inc